What happens when a disease, hidden in plain sight, claims over a million lives each year, yet remains stubbornly resistant to modern medicine? Tuberculosis (TB), caused by Mycobacterium tuberculosis , stands as one of humanity's oldest and deadliest foes, striking hardest in vulnerable communities
I'm thrilled to be speaking with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technological innovation in the industry. Today, we’re diving into the complex world of drug development for rare diseases, with a
In a world where HIV continues to impact millions globally, a groundbreaking effort at The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology in Jupiter, Florida, is sparking hope for a transformative solution. This research hub has embarked on an ambitious journey to
In a landscape where rare diseases often linger in the shadows of medical research, autosomal dominant hypocalcemia Type 1 (AD#), a condition affecting calcium regulation, impacts thousands with limited treatment options. With an estimated 12,000 individuals in the U.S. grappling with this
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose extensive experience in research and development, coupled with a keen understanding of technology and innovation, makes him a leading voice in the industry. Today, we’re diving into the FDA’s recent push to accelerate
During a global health crisis like the COVID-19 pandemic, the race to produce and distribute vaccines revealed a staggering reality: traditional quality control methods could delay production by days or even weeks, risking lives and stalling response efforts. This urgency has spotlighted an
